1. Home
  2. INTT vs TRDA Comparison

INTT vs TRDA Comparison

Compare INTT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo inTest Corporation

INTT

inTest Corporation

BUY

Current Price

$15.70

Market Cap

234.0M

Sector

Technology

ML Signal

BUY

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.72

Market Cap

274.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTT
TRDA
Founded
1981
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.0M
274.5M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
INTT
TRDA
Price
$15.70
$7.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$13.50
$21.00
AVG Volume (30 Days)
267.6K
287.3K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$66,801,000.00
$25,421,000.00
Revenue This Year
$15.82
$39.97
Revenue Next Year
$9.10
$50.80
P/E Ratio
$261.67
N/A
Revenue Growth
66.06
N/A
52 Week Low
$6.63
$4.93
52 Week High
$20.00
$16.45

Technical Indicators

Market Signals
Indicator
INTT
TRDA
Relative Strength Index (RSI) 43.20 53.92
Support Level $14.89 $5.75
Resistance Level $19.64 $10.82
Average True Range (ATR) 1.32 0.50
MACD -0.11 0.23
Stochastic Oscillator 12.11 80.10

Price Performance

Historical Comparison
INTT
TRDA

About INTT inTest Corporation

inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: